Merging researchers 4 hormones that contribute to weight loss into one drug, and the researchers hope that the use of the drug will not be limited to treating obesity, but rather treats related conditions such as type 2 diabetes, cancer and cardiovascular disease. The researchers designed the new compound in the hope that it would be more effective with lower side effects.
The study was conducted by researchers from the Department of Chemistry at the University of Tats in Massachusetts in the United States, and its results were published in the Journal of the American Chemical Society on June 3, and the Yurrick Alert website was written about.
It stimulates our intestine and integration a hormonal measure in our bodies that regulates glucose levels (blood sugar) and tells us when we eat enough food. The Glucagon-Like Peptide 1 is launched to help stimulate insulin production and absorb glucose in muscles and other tissues. While the cells are full of glucose, the level of glucose in the blood is due to normal.
OzemPIC-the commercial name of the medicine of Simiglotide-is used by glucagon-1 peptide with slight adjustments to increase its availability in the bloodstream. Its success in controlling the level of glucose in the blood has prompted the American Diabetes Association to recommend it and other drugs based on the brockagon-1 peptide as first degree treatments for diabetes before insulin.
The glujon-1 peptide also directly affects the brain, which makes us feel full after eating, and slows down the emptying rate of the stomach contents in the intestine, which leads to a more regular release of nutrients and glucose in the bloodstream. For this reason, it has become very common as a treatment for weight loss. However, this drug remains perfect for weight loss.
“The biggest problem is in the glutagon-1 peptide-1 drugs in the need to inject them once a week, and it may cause a strong feeling of nausea. It stops 40% of people who use these drugs to use after the first month,” says Krishna Kumar, a study researcher from the Department of Chemistry at the University of Tafs, Massachusetts in the United States.
Other goals
Another hormone that is excreted after eating is the Glucose-Dependent Insulinotropic Peptide and makes us feel full.
It is very similar to the glucose-based peptide-based peptide-1, so instead of giving two medications, the researchers invented one peptide that combines the two compounds, in what is called the development of medications in the Chemira.
This medication, called Monjaro or Zepbound, is the two commercial Asman for Terzopatid, with an additional benefit represented in significantly reducing nausea, and may outperform the Azmbek in the weight loss market.
“Then there is a third hormone, which is glucagon,” he says.
By adding glucagon to this mixture, both the glutagon-1 peptide and the infection-based infection are equivalent to glucose effect of glucose enhanced glucose, leaving the remaining functions of the three hormones work together to enhance weight loss.
The glujagon is also similar in its composition to the gluxagon-1 peptide and insulin peptide, so the developers of the pharmaceutical pharmaceuticals in Cimiria invented one that includes elements of the three hormones, which can be identified through its three separate receptors. This drug, called Retatrudide, is currently undergoing experiments indicating the possibility of a greater weight loss.
Kumar said, “The goal that people seek to achieve is to reach the level of obesity surgery,” a surgery that greatly reduces the size of the stomach, and can achieve a long -term weight loss of 30%.
“For individuals who suffer from chronic obesity and associated cases that may be fatal, this treatment becomes necessary, but surgical.”
Reaching the gold standard for weight loss with a fourth goal
Current weight loss drugs are still less than this golden standard, so the University of Tafs University focuses on redesigning a drug that can achieve the result of weight loss by 30%.
“There is another hormone that we wanted to add to the completion of the quadruple to control weight, this is called the PYY peptide. The intestine also secretes this molecule after eating, and its function is to reduce appetite and slow down the process of emptying the stomach from food, but with different mechanisms from the similar peptide Glloxon-1 or insulin peptide dependent on glucose.
The Wi-Wi-Wi-Wi-Wi is affiliated with the category of separate hormones and is not structurally associated with the first three categories, so it was not easy to integrate its structure into a hybrid peptide that also mimics the brockagon-1 peptide and the insulin peptide based on glucose and glucagon. Instead, the University of Tatz team managed to link two parts of the peptide together, which led to the innovation of a candidate medicine to be “quadruple”.
“One of the current drugs is that individual contrast, including how they respond to the corresponding hormones, can lead to the results of lower weight loss than the desired in many patients,” said Martin Pinporen, a study researcher from the Department of Chemistry at the University of Tafs.
“By influencing 4 different hormonal receptors at the same time, we hope to improve the opportunities for this contrast to achieve a greater and more stable effectiveness.”
Benporne pointed out that lifestyle changes should be complementary to drug therapy, and said, “The second problem is that patients tend to be overweight after stopping taking brockagon-1 peptide medications currently available.” This double approach will not only support and maintain the target weight, but may also help in maintaining the mass of bone and muscles.
He added, “Recent studies indicate that the weight restoring after stopping taking the drug is delayed with the simulations of the most modern and most effective glutagon-1 peptide.